Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 579 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Increase Protein Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy

NCT03115515
View directory record Official record
Conditions
Pregnancy Related, Thyroid
Interventions
levothyroxine
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 3, 2026, 2:31 AM EDT
Active, not recruiting Not applicable Interventional Results available

Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk

NCT04325308
View directory record Official record
Conditions
Prematurity; Extreme, Feeding Disorder Neonatal, Breast Milk Expression, Growth Failure, Microbial Colonization
Interventions
Protein-enriched human milk diet, Usual human milk diet
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 4 Days
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intradiscal rhGDF-5 Phase I/II Clinical Trial

NCT00813813
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Intradiscal rhGDF-5
Drug
Lead sponsor
DePuy Spine
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Durango, Colorado • Marietta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 3, 2026, 2:31 AM EDT
Recruiting Phase 2 Interventional

Neurovascular Transduction During Exercise in Chronic Kidney Disease

NCT02947750
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
6R-BH4, 6R-BH4 placebo, Folic acid, Exercise training, Stretching, Histidine and beta-alanine supplementation, Histidine and beta-alanine placebo
Drug · Other · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

NCT03297463
View directory record Official record
Conditions
Metastatic Melanoma, Pulmonary Metastases, Hepatic Metastases, Brain Metastases
Interventions
Interleukin-2 & Ipilimumab (P-Ib), Interleukin-2 & Ipilimumab (P-II)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB

NCT00073593
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Surgery
Interventions
Bivalirudin, Heparin, Protamine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2011 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 4 Interventional

A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

NCT00153868
View directory record Official record
Conditions
Anemia, Cancer
Interventions
darbepoetin alfa
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Not applicable Interventional Results available

The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease

NCT00371293
View directory record Official record
Conditions
Sleep Apnea Syndromes, Inflammation
Interventions
Weight Loss Program, CPAP therapy
Behavioral · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Duloxetine Versus Pregabalin for Alcohol Dependence

NCT00929344
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Pregabalin, Duloxetine, Standardized behavioral therapy, Placebo
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 3, 2026, 2:31 AM EDT
Not listed Not applicable Interventional

N-acetylcysteine in the Treatment of Depressive Symptoms in Bipolar Offspring

NCT02865629
View directory record Official record
Conditions
Depression
Interventions
N-acetyl cysteine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 24 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 3, 2026, 2:31 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

"PTHrP(1-36) IV Dose Escalation Study"

NCT00177411
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid Hormone-related Protein
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 3, 2026, 2:31 AM EDT
Terminated No phase listed Observational

Cognitive Changes With Gabapentin Treatment

NCT04106011
View directory record Official record
Conditions
Neuralgia Peripheral, Pain
Interventions
Gabapentin, BTACT, BPI, HADS, SLP9, NPSI
Drug · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy

NCT00805753
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
ACTH
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2 Interventional

A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism

NCT05187377
View directory record Official record
Conditions
Phelan-McDermid Syndrome, Autism Spectrum Disorder (ASD)
Interventions
Growth Hormone, Saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
2 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

NCT01767519
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Pregabalin and Acetaminophen in Healthy Volunteers

NCT04265456
View directory record Official record
Conditions
Postoperative Pain
Interventions
Pregabalin 100mg, Acetaminophen 1300mg
Drug
Lead sponsor
Nevakar, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 4 Interventional Results available

Angiotensin II in General Anesthesia

NCT03733145
View directory record Official record
Conditions
Hypertension
Interventions
Angiotensin II
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Pregabalin in Patients With Radicular Pain

NCT00908375
View directory record Official record
Conditions
Neuropathy; Radicular, Lumbar, Lumbosacral, Failed Back Surgery Syndrome, Spinal Stenosis, Herniated Disc
Interventions
Pregabalin, Sugar Pill
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)

NCT00895141
View directory record Official record
Conditions
Dyslipidemia
Interventions
Saturated Fat Diet
Dietary Supplement
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Sep 3, 2026, 2:31 AM EDT
Terminated Phase 4 Interventional Results available

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

NCT02793154
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide, Albiglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 3, 2026, 2:31 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Bone Remodeling
Interventions
exenatide, Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

NCT02037555
View directory record Official record
Conditions
Cardiac Surgery, Cardiopulmonary Bypass
Interventions
AT-III (Human), Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
41
States / cities
Orange, California • San Francisco, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 3, 2026, 2:31 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)

NCT07480109
View directory record Official record
Conditions
Obesity, Women (Between 30 to 60 Years Old)
Interventions
Protein Rich Foods
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 3, 2026, 2:31 AM EDT